NDAORALTABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
Approved
Jun 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
LANSOPRAZOLE (lansoprazole) by Bridge Therapeutics is proton pump inhibitors [moa]. First approved in 2016.
Drug data last refreshed 12h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Lansoprazole is a proton pump inhibitor (PPI) available as an orally disintegrating delayed-release tablet, approved by the FDA in June 2016. It reduces gastric acid production by inhibiting the proton pump in parietal cells. The drug is indicated for acid-reflux disorders and related gastrointestinal conditions in patients requiring oral acid suppression therapy.
Peak9.6 years to LOE
Product is in peak commercial stage with stable market position; teams are focused on maximizing market penetration and operational efficiency rather than growth initiatives.
Mechanism of Action
Proton Pump Inhibitors
Pharmacologic Class:
Proton Pump Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Maintenance of Healing in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
Started Mar 2026
0GERD (Gastroesophageal Reflux Disease)
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
Started Sep 2025
500 enrolled
GERD (Gastroesophageal Reflux Disease)
Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 Months
Started Jun 2025
0Pediatric Gastroesophageal Reflux Disease
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
Started May 2023
24 enrolled
Erosive Esophagitis
The Efficacy and Safty of Proton Pump Inhibitor (Lansoprazole)
Started May 2023
300 enrolled
Coronary Artery Disease
Worked on LANSOPRAZOLE at Bridge Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.